LY96 and Sepsis: Finally, while TLR4 inhibitors have demonstrated efficacy in murine models of sepsis, prior human clinical trials using a pharmacological antagonist of the MD2–TLR4 complex in patients with severe sepsis failed to show a significant difference in the primary endpoint of 28-day all-cause mortality, despite comparable side effect profiles between treatment and placebo groups.12